🇺🇸 FDA
Patent

US 11235026

Methods and compositions for modulating PD1

granted A61KA61K35/17A61K38/00

Quick answer

US patent 11235026 (Methods and compositions for modulating PD1) held by Sangamo Therapeutics, Inc. expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sangamo Therapeutics, Inc.
Grant date
Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K35/17, A61K38/00, A61K38/1709, A61P